1-11 of 11
Dennis Carney
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

Ashley Whitechurch, Rory Bennett, Shafqat Inam, Benjamin Hartog, Rebecca Blackwood, Shevon Fernando, Felanita Hutani, Hadley Bortz, Mitchel Lincoln, Dennis Carney, Andrew W Roberts, Mary Ann Anderson, Constantine S. Tam, John F. Seymour
Journal: Blood
Blood (2022) 140 (Supplement 1): 9911–9912.
https://doi.org/10.1182/blood-2022-165609
Published: 2022
Journal Articles

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Meaghan Wall, MBBS, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4431.
https://doi.org/10.1182/blood-2018-99-113905
Published: 2018
Journal Articles

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, MBBS, Mary Ann Anderson, FRACP, FRCPA, MBBS, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Sasanka Handunnetti, MBBS, Dennis Carney, Max Wolf, FRACP, FRCPA, MBBS, Surender Juneja, MD, David Alan Westerman, MBBS, FRCPA, FRACP, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1876.
https://doi.org/10.1182/blood-2018-99-114048
Published: 2018
Journal Articles

Interim Analysis of Lenalidomide Consolidation on Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Following Initial FCR Chemotherapy - CLL6 Residuum Study of the Australian Leukaemia and Lymphoma Group (ALLG) and the French Innovative Leukemia Organization (FILO)

David Gottlieb, MBBS MDFRACP FRCPA, Thérèse Aurran, MD, Constantine S. Tam, MD, Mary Sartor, PhD, Rémi Letestu, MD PhD, Dennis Carney, Gavin Cull, MBBS DM FRACP FRCPA, Vincent Levy, MD PhD, Veronique Leblond, MD PhD, Marie Christine Bene, Andrew Budniak, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Florence Cymbalista, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2053.
https://doi.org/10.1182/blood.V128.22.2053.2053
Published: 2016
Journal Articles

Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Constantine Tam, MBBS, MD, Mary Ann Anderson, MBBS, David S. Ritchie, MDPhD, E. Henry Januszewicz, MBBS, Dennis Carney, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD
Journal: Blood
Blood (2015) 126 (23): 2939.
https://doi.org/10.1182/blood.V126.23.2939.2939
Published: 2015
Journal Articles

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Seong Lin Khaw, MBBS, David C. Huang, MD, PhD, Simon He, MBBS, John F Seymour, MBBS, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Kylie D. Mason, MBBS, PhD, Brenda Chyla, PhD, Elizabeth Litvinovich, MSc, Evelyn McKeegan, PhD, Andrew Krivoshik, MD, PhD, Sari Enschede, MD, Rod Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2009) 114 (22): 2374.
https://doi.org/10.1182/blood.V114.22.2374.2374
Published: 2009
Journal Articles

An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Andrew W. Roberts, MBBS, PhD, John F Seymour, MB, BS, PhD, FRACP, Jennifer R Brown, MD, PhD, William G Wierda, Thomas J. Kipps, MD, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Hao Xiong, Ph.D., Yue Cui, PhD, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood
Blood (2009) 114 (22): 883.
https://doi.org/10.1182/blood.V114.22.883.883
Published: 2009
Journal Articles

The Frequency, Manifestations and Duration of Prolonged Cytopenias after First Line Fludarabine-Combination Chemotherapy for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Saar I. Gill, Dennis Carney, David S. Ritchie, Max Wolf, David Westerman, H. Miles Prince, Henry Januszewicz, John F. Seymour
Journal: Blood
Blood (2008) 112 (11): 3176.
https://doi.org/10.1182/blood.V112.11.3176.3176
Published: 2008
Journal Articles

The Addition of Systemic High-Dose Methotrexate (HD-MTX) to Intrathecal Chemotherapy (IT) for Central Nervous System (CNS) Prophylaxis Substantilly Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study

Kirsten Herbert, MBBS, FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Dennis Carney, MBBS, FRACP, FRCPA, David Alan Westerman, MBBS, FRACP, FRCPA, Henry Januszewicz, MBBS, FRACP, FRCPA, Simon Harrison, MBBS, PhD, David Ritchie, MBChB, FRACP, FRCPA, PhD, H. Miles Prince, John Francis Seymour, MBBS, FRACP, PhD
Journal: Blood
Blood (2008) 112 (11): 3596.
https://doi.org/10.1182/blood.V112.11.3596.3596
Published: 2008
Journal Articles

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Miles Prince, MBBS, Hang Quach, MBBS, Paul Neeson, MBBS, Mitch Keegan, Michael Copeman, MBBS, Stefan Peinert, MBBS, Mark Bishton, MBBS, Max Wolf, MBBS, David Ritchie, MBBS, John F. Seymour, MBBS, Dennis Carney, MBBS, David Westerman, MBBS, Simon Harrison, MBBS
Journal: Blood
Blood (2007) 110 (11): 1167.
https://doi.org/10.1182/blood.V110.11.1167.1167
Published: 2007
Journal Articles

Pax-5 Demonstrates Residual B-Cells in Bone Marrow Trephines Post Anti-CD20 Immunotherapy.

Alwyn D’Souza, MB, ChB, FRACP, Surender Juneja, MBBS, MD, FRCPA, Melanie Trivett, Dennis Carney, MBBS, FRACP, FRCPA, David Westerman, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2005) 106 (11): 5013.
https://doi.org/10.1182/blood.V106.11.5013.5013
Published: 2005